A drug approved for the treatment of dementia appears to improve executive function in adults with attention-deficit/hyperactivity disorder (ADHD) when administered with standard stimulant therapy, preliminary research suggests.

Initial results from the small, randomized controlled trial indicate that adjunctive memantine (Namenda, Forest Laboratories, Inc) with osmotic release oral system-methylphenidate (OROS-MPH) was associated with improvement in ADHD patients with executive function deficits (EFDs).

According to investigators, EFDs produce a wide range of difficulties that affect scholastic achievement in particular as well as the ability to work, plan, organize, and manage time well.

Continue Reading

READ FULL ARTICLE Curated publisher From Med Scape